Schizophrenia Sensory Gating Deficit With Quetiapine

NCT00536783 | Completed DMC

• 2 other identifiers: 0072. IRUSQUET0332
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.

Conditions

Schizophrenia

Keywords

Psychiatry; Antipsychotic; Psychopharmacology; Clinical Trial; Open Label; Schizophrenia; Sensory Gating; Attention; Memory

Interventions

Quetiapine DRUG

Eligibility Criteria

• Age: 18 Years - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Patient Population
• Diagnosis of Schizophrenia as determine by the Structured Clinical Interview for DSM-IV
• No comorbid diagnosis of PTSD
• responders to quetiapine, determined by continuous treatment at the same dose of quetiapine and absence of psychiatric hospitalization for at least 3 months
• No history of drug dependency in their lifetime
• No history of alcohol or other substance abuse in the 6 months prior to entry into the study
• No history of head injury with loss of consciousness for more than 5 minutes
• No history of seizure disorder
• No mood stabilizing agents
• Between 18-65 and
• Able to sign informed consent
• Normal Controls
• Matched in age and gender to patient population
• No history of psychiatric dysfunction or alcohol or other substance dependence in their lifetime as determine by the SCID
• No history of alcohol or other substance abuse in the previous 6 months

You may not qualify if:

• Subjects will be excluded from participating in this study if they:
• Require treatment with a mood stabilizer
• Have had an inpatient hospitalization in the past 3 months
• Have a history of a neurological disorder
• Have any other axis I diagnosis besides schizophrenia

Sponsors & Collaborators

• New Mexico VA Healthcare System: lead
• AstraZeneca: collaborator

Study Sites (1)

New Mexico VA Healthcare System

Albuquerque, New Mexico, 87108, United States

Location

Related Links

• The website for the Biomedical Research Institute of New Mexico which helps administers the funds for this project.

MeSH Terms

Conditions

Schizophrenia

Interventions

Quetiapine Fumarate

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Dibenzothiazepines; Thiazepines; Thiepins; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Jose M Canive, MD

  New Mexico VA Heathcare System / BRINM

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: FED

Study Record Dates

• First Submitted: September 27, 2007
• First Posted: September 28, 2007
• Study Start: April 1, 2004
• Study Completion: March 1, 2006
• Last Updated: December 31, 2007

Record last verified: 2007-09

Locations

US (1)